News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

RHIZOME AND PAUL G. ALLEN FAMILY FOUNDATION ANNOUNCE PARTNERSHIP TO ADVANCE CIVIC EDUCATION IN WASHINGTON SCHOOLS

Paul G. Allen Family Foundation

Seattle, WA — Today, Rhizome and the Paul G. Allen Family Foundation announced a $620,000 initiative aimed at creating a new Civic Service Fellowship program in Washington high schools. This three-year initiative will establish over 100 teams of Fellows in hyperlocal Chapters across the state of Washington. Rhizome’s Civic Service Fellowship prioritizes rural communities, under-resourced areas, and communities of color. The Civic Service Fellowship will empower high school students to lead year-round initiatives designed to boost civic engagement within their schools and communities. This will include organizing community events, educating younger students about democracy, and assisting their eligible peers with voter registration or pre-registration. Students have the opportunity to mend divisions, combat disengagement, and address the mental health crisis by creating civic communities. By inviting students to gain leadership experience and build healthy habits based on who they want to become, Rhizome inspires responsibility and produces pathways for lifelong leadership and public engagement. Civic participation can be an important factor for young people’s social and mental well-being. Recent research from Gallup has found that less than half of Gen Z members feel as though they are “thriving” and only 44% feel prepared for their future. While 76% of young people across the country believe their age group has the power to enact change, only 40% of all youth—and only 34% of youth of color—report feeling well-qualified to participate in politics. In an era marked by diminishing public trust and worsening mental health outcomes among young people, this initiative will equip students with the tools to engage their communities in building a healthier world for all. “After 90 of us came together as Co-Founders of Rhizome just two years ago, we are thrilled to announce this multi-year partnership with the Paul G. Allen Family Foundation, addressing the need for sustainable systems that empower emerging leaders to shape change,” said Jacob Merkle, Rhizome’s CEO. “In an era of unmet challenges to our civic and mental health, this collaboration allows Rhizome to scale our grassroots system, deepen our impact, and build collective power for young people. We’re grateful for the Foundation's recognition that young people are the future. We hope this early commitment will spur philanthropy to provide more scale-enabling, no-strings-attached funding for young people to create the safer, happier, and healthier world they deserve.” “Witnessing the growth of Rhizome from day one has been one of the most fulfilling experiences in my life. Not simply the growth of the organization, but the tangible difference that has been made in the confidence of countless students. As an organizer in Washington, my proudest moment is seeing the transformation in students as they gain their voice to fearlessly advocate for their own beliefs,” said Hiba Siddiqui, a Rhizome Regional Organizer who works in Eastern Washington. “Having the support of partners like the Paul G. Allen Family Foundation reaffirms our mission and gives us the resources to expand our reach. I am excited to see the indelible impact that will be made as Rhizome brings our community of trust, friendship, and belonging to other areas in Washington.” “Civic education is necessary now more than ever. Our civic landscape has shifted and testifies to the urgency to actively involve youth in bettering their communities and solving societal issues. As a committed civic educator for over two decades, I cannot emphasize enough how important it is to have partners in this mission,” said Jen Reidel, a Social Studies and English teacher at Bellingham High School. “I can provide classroom experiences, but I need like - minded civic organizations like Rhizome to help students find their civic identities and mission outside the classroom.” According to Ms. Reidel, Rhizome removes the responsibility of supporting a student club outside of class from the teacher and places it on the students and their Rhizome mentor. It honors student agency and diversity by equipping students to promote civic engagement within their school and identify issues they would like to address at a local level and authentically work toward their solution. Funds from the partnership will directly support student-led efforts by paying a dedicated team of Rhizome’s student organizers in Washington, who will work to implement the Civic Service Fellowship in local schools in their communities. By funding this important work, Rhizome and the Paul G. Allen Family Foundation are investing deeply in the next generation of lifelong civic leaders. About Rhizome Founded in 2021, Rhizome is a national network of student leaders organizing to empower young people to build stronger communities. Rhizome was co-founded by 90 young people to help students become more civically active while training the next generation of organizers and emerging leaders. Learn more at www.werhize.org. About the Paul G. Allen Family Foundation Founded in 1988 by philanthropists Jody Allen and the late Paul G. Allen, co-founder of Microsoft, the foundation invests in communities across the Pacific Northwest to enhance the human experience of arts & culture, center under-served populations, and mobilize young people to make impact. In addition, the foundation supports a global portfolio of nonprofit partners working across science and technology solutions to protect wildlife, preserve ocean health, and create lasting change. The foundation also funds the Paul G. Allen Frontiers Group, which works to advance cutting-edge research in all areas of bioscience. Contact Details Rhizome Maya Rodriguez, Communications Director +1 415-488-7692 mayar@werhize.org Company Website https://www.werhize.org

November 01, 2023 08:00 AM Pacific Daylight Time

Image
Article thumbnail News Release

Living with Acromegaly: Spreading Awareness and Highlighting Treatment Options on Acromegaly Awareness Day

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/y696riLIIKs For more information, visit MYCAPSSA.COM Acromegaly is a rare condition that affects about 25,000 people living in the U.S. It is caused by a benign tumor in the pituitary gland which is located just beneath the brain. This benign tumor makes too much growth hormone, and this can cause various issues such as fatigue, headaches, and increased growth of hands and feet and pretty much every part of the body. If not treated, acromegaly can cause high blood sugar as in Diabetes and high blood pressure, and sometimes cause serious damage to the heart which can be life-threatening. The good news is that there are some very good treatments available to help control the problem. A nationwide media tour was conducted on October 23rd to discuss the drug MYCAPSSA as well as to hear about the experiences of someone living with acromegaly. The media tour featured Dr. Anthony P. Heaney, Professor at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) and Becky Bierman, a person living with acromegaly. Mycapssa, is a twice-daily oral medication that reduces the production of growth hormone and is designed for people who have previously been on an injectable version of octreotide therapy for the long-term maintenance of acromegaly. During the media tour Dr. Heaney and Becky discussed: · What acromegaly is and how many people it affects. · What it is like living with acromegaly. · Treatment options available for someone living with this disease. People diagnosed with acromegaly considering a new treatment option should talk to their doctors first. For more information, you can visit www.Mycapssa.com Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 01, 2023 09:57 AM Eastern Daylight Time

Video
Article thumbnail News Release

HKBU studies show over half of COVID-19 patients have post-disease syndrome

Hong Kong Baptist University

HONG KONG SAR - Media OutReach - 1 November 2023 - The School of Chinese Medicine at Hong Kong Baptist University (HKBU) found that 55% of the patients who sought medical treatment from the "HKBU Chinese Medicine Telemedicine Centre Against COVID-19" during the fifth wave of the COVID-19 pandemic continued to experience at least one long COVID symptom for six months to a year after diagnosed with an infection. The most common symptoms are fatigue, brain fog and cough. Professor Bian Zhaoxiang, Director of the Clinical Division at HKBU’s School of Chinese Medicine (middle), together with his research team members Mr Cheung Chun-hoi, Associate Director of the Clinical Division (2nd left); Dr Zhang Jialing, Postdoctoral Fellow of the Centre for Chinese Herbal Medicine Drug Development (1st left); Mr Luo Jingyuan and Wong Hoi-ki, PhD students (2nd and 1st right) of SCM at HKBU, analyse patient statistics to deepen the medical community’s understanding of the symptoms during the early and middle stages of COVID-19 infection as well as the post-COVID syndrome. The study also revealed that patients who took Chinese medicine after COVID-19 infection took a shorter time to test negative in rapid tests, and experienced significant symptom relief compared to patients who did not take Chinese medicine. The research findings have been published in a number of papers in international academic journals including the Journal of Medical Virology and The American Journal of Chinese Medicine. HKBU established the "HKBU Chinese Medicine Telemedicine Centre Against COVID-19" in 2021 during the fifth wave of the COVID-19 pandemic in Hong Kong to provide free telemedical services for COVID-19 patients. Making reference to the treatment protocols and clinical experiences in Mainland China, the expert team of HKBU's School of Chinese Medicine formulated the "Chinese Medicine Clinical Guidelines for COVID-19 in Hong Kong" as the University's clinical diagnosis and treatment standards for COVID-19. The Telemedicine Centre follows the guidelines to provide diagnosis, treatment, and prevention services to COVID-19 patients, close contacts, and caregivers. Coughing is the most common early symptom of infection The HKBU research team led by Professor Bian Zhaoxiang, Director of the Clinical Division at the School of Chinese Medicine, conducted a retrospective study using patient statistics collected by the Telemedicine Centre during the fifth wave of the pandemic. The team analysed the symptoms in the first four weeks of about 13,000 patients who were infected with COVID-19 from mid-March to early May in 2022 and underwent home isolation. The results showed that 93% of patients experienced at least one symptom. The most common symptoms during the first week of infection were cough (91%), sputum (75%), dry throat (50%) and sore throat (44%). 17% of patients still had these symptoms four weeks after infection. Although the symptoms gradually subsided over time, the prevalence of fatigue increased. Chinese medicine accelerates viral clearance Among this batch of patients, the research team selected 311 patients who had taken Chinese medicine for five days within 10 days after diagnosis, and another 311 patients who had not taken any Chine medicine during the same period to evaluate the efficacy of Chinese medicine. The results showed that patients who took Chinese medicine within 10 days after COVID-19 infection needed an average of seven days to test negative in rapid tests, and experienced an average of four symptoms, which were significantly milder compared to patients who didn't take Chinese medicine. The average time to test negative for patients who did not take Chinese medicine was eight days, and they experienced an average of 11 symptoms. The results show that Chinese medicine is an effective treatment for COVID-19 infection. Over half of the patients experience long COVID after six months The research team conducted a follow-up telephone survey from November 2022 to January 2023 with 6,242 COVID-19 patients who sought medical consultation at the Telemedicine Centre between December 2021 and May 2022 to understand their symptoms and risk factors after six months to a year of infection. The study found that 55% of patients still experienced at least one long-term symptom, i.e. "long COVID" or "post-COVID syndrome". The most common symptoms were fatigue (36%), brain fog (34%) and cough (31%). Furthermore, females, middle-aged persons, obese people, those with comorbidities such as ophthalmology or otorhinolaryngology diseases, digestive system diseases, respiratory diseases, hyperlipidemia and cardiovascular diseases, and patients with more initial symptoms were more likely to develop long COVID. However, there was no significant correlation between taking three or more doses of vaccine and the occurrence of long COVID. Professor Bian said: "HKBU established the Telemedicine Centre during the COVID-19 outbreak to provide free treatments for COVID-19 patients. We analysed the Centre's data to deepen the medical community's understanding of the symptoms during the early and middle stages of COVID-19 infection as well as the post-COVID syndrome. It allows the public to understand the effectiveness of Chinese medicine in treating COVID-19. The study also shows that the tele-services of Chinese medicine can be an important component of Hong Kong's healthcare and disease prevention system." To address the issues of long COVID, Professor Bian's team has initiated a series of clinical and basic research, including a survey of COVID-19 patients with diabetes and a clinical trial conducted in collaboration with other partners to investigate the efficacy, safety and action mechanism of senlingcao oral liquid in treating long COVID fatigue. These projects aim to further explore the impact of COVID-19 and its treatment options. Contact Details Christina Wu christinawu@hkbu.edu.hk

November 01, 2023 09:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

Elsevier Partners with the Korean Society for Molecular and Cellular Biology to Publish Molecules and Cells

Elsevier

The Korean Society for Molecular and Cellular Biology (KSMCB), one of the largest and most prominent academic societies in the field of life sciences in Korea, and Elsevier, a leader in information and analytics for customers across the global research and health ecosystems, are pleased to announce a new partnership to publish Molecules and Cells, the flagship journal of KSMCB. This English-language publication will be hosted on Elsevier’s industry-leading online platform of peer-reviewed literature, ScienceDirect, beginning January 1, 2024. Continuing as a Gold Open Access, online-only publication, all articles will be immediately and permanently free to read and download. Junho Lee, PhD, Professor, Department of Biological Sciences, Seoul National University and President of KSMCB, commented, “It is with great pleasure that I would like to announce that KSMCB has entered into a co-publishing agreement with Elsevier. The rationale behind this decision is to meet the challenges of an ever-changing publishing environment and the growing needs of society members and scientific colleagues. We will be able to take advantage of the global network and professionalism that Elsevier brings, which will result in the recognition that our journal strives to achieve on the global stage. We envision that Molecules and Cells will make a giant leap forward in the near future to becoming a premier international scientific journal of which we can all be proud.” Launched in 1990 and now in its 46th volume, Molecules and Cells has continually solidified its position as a leading journal in the fields of molecular and cellular biology. It has published articles in English from more than 30 countries on its way to becoming a globally recognized journal. Since 1995, the journal has been indexed in Web of Science/Science Citation Index-Expanded, the first Korean journal in the biological sciences to be accepted for inclusion in this service. Molecules and Cells continues its tradition of publishing excellence under the expert leadership of Editor-in-Chief Jae Bum Kim, PhD, supported by an eminent editorial board. After earning his doctoral degree in the Department of Microbiology & Molecular Genetics, Harvard University, Prof. Kim has held a number of prestigious academic appointments in Korea and the United States. He is currently Professor in the Department of Biological Sciences and serves as the Director of the Center for Adipose Tissue Remodeling, Creative Research Initiatives, Center for Studies on Structure-Function in Adipocyte at Seoul National University. Prof. Kim noted, “The editorial team, editorial board, KSMCB leadership, and I remain passionate and committed to timely publication of the highest quality scholarly work. We anticipate that Elsevier’s exceptional level of publishing expertise and professionalism will help bring the journal to a wider worldwide audience of authors and readers more efficiently and effectively, providing greater opportunities for collaboration and knowledge sharing.” The journal will expand its impact and outreach through availability via ScienceDirect, which will host 33 years of Molecules and Cells back volumes (from 1990 onwards). ScienceDirect has 1 billion annual visits and over 17,000 licenses worldwide. Manuscripts may be submitted via Editorial Manager. Accepted manuscripts, on average, will be available online within 48 hours in a pre-release format. Molecules and Cells is covered in important abstracting and indexing services including Science Citation Index-Expanded (current Journal Impact Factor 3.8), Scopus (current CiteScore 6.9), PubMed, Current Contents®/Life Sciences, and Chemical Abstract Service. Louise Curtis, Elsevier Senior Vice President, Life Sciences, Social Sciences, Economics, remarked, “We are delighted that KSMCB has selected Elsevier as its partner, and we are proud to publish this well-established, well-run open access journal. It is an excellent complement to the Elsevier molecular and cell biology journal portfolio, expanding our author base into the Korean scientific community. We are committed to providing the best possible support for KSMCB’s mission and community and fostering an international exchange of cutting-edge research.” Notes for editors About Molecules and Cells Molecules and Cells is an international online open access journal devoted to the advancement and dissemination of fundamental knowledge and ground-breaking research in all areas of cellular and molecular biology. Publications cover a broad range of topics of general interest but should be within relevant fields of biology. It is the official journal of the Korean Society for Molecular and Cellular Biology. www.sciencedirect.com/journal/molecules-and-cells About the Korean Society for Molecular and Cellular Biology (KSMCB) The Korean Society of Molecular and Cellular Biology (KSMCB) was founded in 1989. During the last 30 years, KSMCB has grown into one of the largest and most prominent academic societies in the life sciences in Korea. KSMCB serves as a platform for molecular and cellular biologists outside Korea as well, providing them with the opportunity of collaboration and knowledge of cutting-edge research trends. The Society publishes Molecules and Cells, a molecular biology journal with a broad subject coverage and readership, and hosts an annual international conference, a forum for cutting-edge research in all areas of molecular and cellular biology. www.ksmcb.or.kr/eng About Elsevier and society partnerships Elsevier has long-standing partnerships with over 600 learned societies worldwide, helping them to realize their missions and inspire and support their communities. We pride ourselves on consistently delivering outstanding publishing outcomes through strategic insight, reliable finances, global dissemination, embracing open science and open access, and championing the needs of the communities we jointly serve. www.elsevier.com/societies About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, academic leaders, funders, R&D-intensive corporations, doctors, and nurses. Elsevier employs 9,000 people worldwide, including over 2,500 technologists. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on over 2,800 journals, including The Lancet and Cell; 46,000+ eBook titles; and iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. Contact Details Carolien van der Zanden Senior Marketing Communications Manager, Elsevier c.zanden@elsevier.com Jae Bum Kim Editor-in-Chief, Molecules and Cells jaebkim@snu.ac.kr Company Website https://www.elsevier.com/

November 01, 2023 09:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

DPH Biologicals, University of Illinois Team Up to Improve Crop Residue Management

DPH Biologicals

• Trials focus on benefits of biologicals for post-harvest stubble control • First-year results unveiled October 30 at international agronomy sciences meeting DPH Biologicals and the University of Illinois Urbana-Champaign (UIUC) announced today a research collaboration validating the impact biologicals make to accelerate decomposition of crop residue, thereby unlocking the adoption of more sustainable and profitable farming practices for United States high-yield, broadacre growers. Starting in spring of 2023, the UIUC Crop Physiology Lab run by Fred Below, Ph.D. and Connor Sible, Ph.D., began researching the impact of microbial solutions in crop residue management including the use of TerraTrove® Residuce®, technology developed by DPH Bio. Residuce is a biodigester, a biological specifically formulated to accelerate the process of plant tissue degradation. “Supporting Dr. Below’s lab is an opportunity to ground-truth the benefits of biodigesters, understand how technologies like Residuce can enable more sustainable and profitable cropping practices and to develop best practice use recommendations supporting our retail and channel partners with high-value, science-verified cropping solutions,” said Alex Cochran, Ph.D., DPH Bio’s Chief Technology Officer. A subset of biofertilizers, biodigester sales are exploding as part of the expanding global biofertility market, projected to reach $3.75 billion USD in sales by 2030, a CAGR of 12.80%, underpinned by market demand for more sustainably-grown food with farmers’ need to offset increasing costs and shrinking profit margins. Residuce, available in a liquid and dry formulation, is currently used on 1.5 million North American acres, a 50% growth rate in the past year. Already, early UIUC trial results indicate improved yields when biodigesters were used with cover crop plantings. Cover crops are typically associated with lower yields, a correlation that has discouraged grower adoption despite the well-known soil health benefits of cover cropping. Using Residuce on an unmanaged cereal rye cover crop partially eliminated the nearly nine-bushel yield penalty average experienced when a cover crop is planted between no-till corn and soybean rotations, according to research presented Monday by UIUC graduate student Darby Danzl at the 2023 ASA, CSSA, SSSA International Annual Meeting, held jointly by the American Society of Agronomy, the Crop Science Society of America and the Soil Science Society of America. The yield penalty was nearly fully eliminated when a fertilizer source was combined with Residuce. Research Focuses on Value-Creation of Biodigesters for Corn, Soybean and Wheat Production With UIUC already a research leader in residue management strategies in broadacre cropping systems, the ongoing field trial collaborations with DPH Bio will focus on further defining the value biodigesters bring to unlocking the value of residue for sustainable agriculture. DPH Bio recently published “ Rethinking Crop Residue Management with Biodigesters,” an analysis of research into crop residue management, includes work already completed by the UIUC crop physiology lab as well as DPH Bio’s field trial results. The UIUC-DPH partnership will expand upon the research and benefits of biodigesters presented in the white paper. Large volumes of crop residue create problems, Sible said, with high-yielding cultivars and practices like no-till, double-cropping and cover cropping generating more residue than growers’ have ever experienced. Today’s average 180-bushel corn crop yields 3.9 tons per acre of corn stover and every additional bushel in yield contributes another 43.7 pounds of stover, according to UIUC research. Growers complain of delayed germination, poor plant stands, nutrients locked up in the decomposing process, increased disease and pest outbreaks from pathogens that overwinter in thick residue layers and yield penalties associated with residue accumulation. Yet, once broken down, residue is an untapped source of nutrients and better soil and crop health. Strategies for accelerating residue degradation are key, Below said. “Residue is nature’s biological. It’s so good for the soil and the plant, and there's a lot of nutrition there. But residue can be your best friend or your worst nightmare,” Below said. “The quicker you can degrade residue, the easier you can plant, the more uniform your crop is going to emerge and the more likely you’re going to get the benefits of that residue.” The next round of joint UIUC-DPH Bio trials will focus on: ● The benefits of biodigesters for cover crop management in no-till corn and soybean. ● Fall versus spring residue management with biodigesters to benefit continuous corn yield. ● Biodigesters value to residue management in a wheat-soybean double crop rotation. Studies conducted in 2023 will be available this winter. The second round of trial results will be available before the 2025 planting season. About DPH Biologicals DPH Biologicals aims to be the industry’s most trusted biologicals provider. We attract, develop and scale technologies improving broad market access and simplifying the grower experience with biologicals. With more than three decades invested into scientific research, field-testing, partner relationships and product development, we’ve built three proven product platforms – BellaTrove® for biocontrols; TerraTrove® for biofertility and biodigesters; and RegenAphex™, a regenerative, plant-based humus extract that serves as a foundation for our flagship biofertilizer SP-1 Classic and a platform for third-party technological development. For more information, visit www.dphbio.com. Contact Details AgTech PR for DPH Bio Georgie Smith georgie@agtechpr.com Company Website http://www.dphbio.com

November 01, 2023 08:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

CURE ALZHEIMER’S FUND RECEIVES $50,000 GRANT FROM GREATER TOLEDO COMMUNITY FOUNDATION

Alzheimer’s Disease Research Foundation

Cure Alzheimer’s Fund (CureAlz), a non-profit dedicated to funding the most promising research to end Alzheimer’s disease, received a $50,000 grant from the Robert A. Stranahan, Jr. Charitable Advised Fund of the Greater Toledo Community Foundation. This grant represents their largest gift to Cure Alzheimer’s Fund since the Robert A. Stranahan, Jr. Charitable Advised Fund made its first grant to the non-profit in 2016. Through eight years of consecutive giving, the fund has provided $235,000 to CureAlz scientists working to find a cure. “Year after year, we are more encouraged by the progress Cure Alzheimer’s Fund is making to understand Alzheimer’s disease,” said Keith Burwell, President of Greater Toledo Community Foundation. “Our continued philanthropic support provides necessary funding for research that accelerates the discoveries that will eventually tackle Alzheimer’s disease and find a cure.” “The Greater Toledo Community Foundation recognizes the physical, emotional and financial impact this disease has on so many families in its community and around the world and has been a wonderful partner to CureAlz in our mission to find a cure,” said Meg Smith, CEO of Cure Alzheimer’s Fund. “Alzheimer’s devastates not just individual patients but their family and community as well. Developing effective, accessible therapies requires deep understanding of the complex causes and pathologies of Alzheimer’s. The scientists CureAlz supports are pursuing vital high-risk, high-reward research to accelerate progress. We are deeply grateful to the Greater Toledo Community Foundation for sharing our goal to end the burden of Alzheimer’s.” It is estimated that more than 6.5 million Americans are currently living with Alzheimer’s disease, a number that is expected to increase rapidly as the Baby Boomer generation continues to age. It is projected that the share of adults 65 and older in the US population will rise to 22 percent by 2050. With age as the biggest risk factor, Alzheimer’s disease is poised to place an unmanageable financial burden on the US healthcare system, caregivers, and loved ones. With the philanthropic support of the Robert A. Stranahan, Jr. Charitable Advised Fund of the Greater Toledo Community Foundation and tens of thousands of other donors, CureAlz has been able to direct more than $180 million to Alzheimer’s disease research since its inception in 2004 and has delivered critical breakthroughs for the research community. About Greater Toledo Community Foundation Greater Toledo Community Foundation is a public charitable organization created by citizens of our community to enrich the quality of life for individuals and families in our area. In existence since 1973, the Foundation has more than 970 individual current funds with assets of approximately $406 million. The Foundation provides philanthropic services for individuals, families, businesses and corporations to meet their charitable giving needs. For more information on the Foundation, visit the organization’s website at www.toledocf.org or follow them on Facebook or LinkedIn. About Cure Alzheimer’s Fund Cure Alzheimer’s Fund is a non-profit dedicated to funding the most promising research to prevent, slow, or reverse Alzheimer’s disease. Since its founding in 2004, Cure Alzheimer’s Fund has provided grants to the world’s leading researchers and contributed more than $180 million to research. Its funded initiatives have been responsible for many key breakthroughs in understanding the causes and pathology of Alzheimer’s disease. Cure Alzheimer’s Fund has received a 4-star rating for more than 12 consecutive years from Charity Navigator. With 100 percent of funds raised going to support research, Cure Alzheimer’s Fund has been able to provide grants to many of the best scientific minds in the field of Alzheimer’s research. For more information, please visit https://www.curealz.org/. Contact Details Barbara Chambers +1 978-417-9890 bchambers@curealz.org

November 01, 2023 05:51 AM Eastern Daylight Time

Article thumbnail News Release

Perimeter Medical Imaging AI initiates new clinical trial site in Seattle, WA

Perimeter Medical Imaging AI

Adrian Mendes, the CEO of Perimeter Medical Imaging, joined Steve Darling from Proactive with news that the company has initiated an additional clinical trial site at the University of Washington in the Fred Hutch Cancer Center. Perimeter's clinical trial is a multi-center, randomized, two-arm pivotal study that evaluates the investigational Perimeter B-Series Optical Coherence Tomography (OCT) technology. This technology is combined with Perimeter's proprietary ImgAssist AI software and is used during breast conservation surgeries. The core of this innovative approach is the use of ultra-high-resolution, real-time, advanced imaging tools to examine excised tissues at the cellular level, providing crucial insights to surgeons. Mendes emphasized the significance of this additional clinical trial site, as it plays a vital role in gathering valuable data generated during the study. This data will be instrumental in supporting the commercialization of Perimeter's B-Series technology. The company's ultimate goal is to transform cancer surgery by providing advanced technology that not only improves patient outcomes but also helps reduce healthcare costs. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

October 31, 2023 03:22 PM Eastern Daylight Time

Video
Article thumbnail News Release

1606 Corp announces cutting-edge AI-driven CHATCBDW is live and in operation

1606 Corp.

1606 Corp CEO Greg Lambrecht joined Steve Darling from Proactive to share news the company has officially unveiled its cutting-edge AI chatbot, ChatCBDW, which represents a significant advancement in the world of CBD products and customer engagement. Lambrecht explained that ChatCBDW has undergone key designs and rigorous testing before being launched and is now live and operational. This innovative chatbot offers a wide range of user-centric features that go beyond the ordinary. One of its standout attributes is its capability to respond to user inquiries and provide comprehensive education on all aspects of CBD. However, ChatCBDW doesn't stop there. It takes personalization to the next level by offering tailored product recommendations to users and engaging in conversations that closely mimic human interaction. This level of innovation empowers customers to make well-informed choices, explore a diverse array of CBD products, and promises an unparalleled shopping experience within the CBD industry. The seamless integration of ChatCBDW with Microsoft Azure is a key component of its capabilities. Microsoft Azure is renowned for its scalability, unwavering reliability, and cutting-edge AI functionalities. This integration ensures that ChatCBDW can operate impeccably, even during periods of peak demand, delivering users a consistently responsive and seamless experience throughout their interaction with the chatbot. The company has also announced that Cool Blue Distribution is now a North American licensed reseller of ChatCBDW and is set to engage its network of over 800 CBD retailers immediately. The first direct-to-merchant marketing campaign is scheduled to begin by mid-November 2023, with the goal of generating notable revenue before January 1, 2024. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

October 31, 2023 03:16 PM Eastern Daylight Time

Video
Article thumbnail News Release

Introducing the TechClusion Fund

Communication Service for the Deaf

CSD Social Venture Fund, a subsidiary of Communication for the Deaf, is proud to announce the launch of a new funding source for tech startups that prioritize inclusion and accessibility for deaf communities. The TechClusion Fund is a groundbreaking initiative that addresses a common oversight in technology development: accessibility. The fund was created with the intention of accelerating technology built by companies that create accessible products and services that benefit the Deaf community. Over the past 30 years, our society has experienced a rapid evolution in technological advancements. While these advancements generally improve our lives, we often see accessibility features added as an afterthought instead of being built into the original product design. This practice makes the user experience less than ideal for both those who do and do not use these features. “Accessible technology doesn’t just benefit Deaf communities,” explained Rosa Lee Timm, President of CSD Social Venture Fund. “When companies design their products with the needs of Deaf or disabled users in mind, they create a better experience for all users.” The TechClusion Fund was started with the intention of addressing these systemic and prevalent issues in tech by ensuring that entrepreneurs and developers are intentionally creating their products with all end-users in mind. “We expect that the impact of the TechClusion Fund will extend beyond the development of accessible products,” shared Greg Bland, Director of Business Development for CSD Social Venture Fund. “By focusing on startups who hope to have a positive impact on Deaf communities, we will see job creation and more opportunities for economic advancement for Deaf individuals.” Unlike CSD Social Venture Fund’s traditional VC funding, TechClusion is open to all tech-startups operating in the United States and not specifically Deaf-owned businesses. Applicants must demonstrate the following: How their work will positively impact Deaf communities. This can be through hiring Deaf and hard of hearing employees, Deaf ownership, or outlining how their product or service will contribute to deaf communities. A commitment to equitably hire Deaf, BIPOC Deaf, and other Deaf groups for various positions at levels of the company, including C-level positions, as the company grows. A commitment to both their company and TechClusion’s investment. For those who are interested in applying or learning more, you can visit CSD Social Venture Fund’s website or contact Rosa Lee Timm at svf@csdsvf.com for more information. CSD's Social Venture Fund is one of the only venture capital firms and incubators in the world supporting Deaf entrepreneurs and Deaf-owned and operated businesses. CSD SVF provides equity investments to Deaf-led businesses that exemplify CSD’s values: enhancing Deaf economic power, employing Deaf people, and creating social change. CSD SVF is committed to the success of each business, providing not only financial investment, but also access to tools and resources, enabling each Deaf-led business to thrive. Existing portfolio members include Mozzeria, National Deaf Therapy, DeafTax, Bus Door Films, Hands on Travel, Hotsy Totsy Haus, 4Legz All Natural Dog Treats and Lochiel Brewing. For more information, please visit https://csdsvf.com/ and follow us on Facebook, Twitter, Instagram, and LinkedIn. About Communication Service for the Deaf Communication Service for the Deaf (CSD) is the largest Deaf-led social impact organization in the world. For more than four decades, CSD has been a leader in creating and providing accessible and innovative solutions for the Deaf community. Today, CSD continues its work to create opportunities for personal and economic growth within the Deaf community, specifically addressing leadership and employment. For more information, please visit CSD and follow us on Facebook, Twitter, Instagram, and LinkedIn. Contact Details Communication Service for the Deaf Molly Miller +1 315-679-8948 mmiller@csd.org Company Website https://www.csd.org/

October 31, 2023 01:12 PM Eastern Daylight Time

Image
1 ... 7879808182 ... 304